MichaelBigbyMDRosamariaCoronaDSc, MDDamianoAbeniMD, MPHPaoloPasquiniMD, MPHMoysesSzkloMD, MPH, DrPHHywelWilliamsMD
Alefacept (Amevive; Biogen Inc, Cambridge, Mass) is a fusion protein that binds to the CD2 receptor on lymphocytes, blocking its interaction with lymphocyte function–associated antigen-3 on antigen-presenting cells. Most lymphocytes in psoriatic lesions are memory effector (CD4+CD45RO+ and CD8+CD45RO+) T cells showing up-regulation of CD2 on their cell surface. By binding preferentially to these cells in psoriasis, alefacept may inhibit their activation and may reduce disease activity.
Luigi Naldi. Alefacept for Psoriasis: Promising Drug, Open Questions. Arch Dermatol. 2002;138(9):1238–1240. doi:10.1001/archderm.138.9.1238